Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue

Molecular Cancer Therapeutics

Volumn 9, Issue 4, 2010, Pages 1058-1069

  More, Swati S ^a   Li, Shuanglian ^a   Yee, Sook Wah ^a   Chen, Ligong ^a   Xu, Zhidong ^b   Jablons, David M ^b   Giacomini, Kathleen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CIMETIDINE; CISPLATIN; CORTICOSTERONE; DISOPYRAMIDE; GLUTATHIONE; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; OXALIPLATIN; PICOPLATIN; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DRUG ANTAGONISM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CIMETIDINE; DNA ADDUCTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; ORGANIC CATION TRANSPORT PROTEINS; PLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950823207     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1084     Document Type: Article

References (23)

1. Zeller JL, Lynm C, Glass RM. Lung cancer. JAMA 2007;297:1022.
2. Gkiozos I, Charpidou A, Syrigos K. Developments in the treatment of non-small cell lung cancer. Anticancer Res 2007;27:2823-2827
3. Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 2002;87:825-833
4. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-584
5. Bunn PA, Jr. Platinums in lung cancer: sufficient or necessary? J Clin Oncol 2005;23:2882-2883
6. Shah N, Dizon DS. New-generation platinum agents for solid tumors. Future Oncol 2009;5:33-42.
7. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998;77:366-373
8. Song IS, Savaraj N, Siddik ZH, et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004;3:1543-1549
9. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci 2002;99:14298-14302
10. Zhang S, Lovejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006;66: 8847-8857
11. Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui K. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Me tab Dispos 2008;36:2299-2306
12. Battle AR, Choi R, Hibbs DE, Hambley TW. Platinum(IV) analogues of AMD473 (cis-[PtCl2(NH3)(2-picoline)]): preparative, structural, and electrochemical studies. Inorg Chem 2006;45: 6317-6322
13. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117:1422-1431
14. Holford J, Raynaud F, Murrer BA, Grimaldi K, Hartley JA, Abrams M, Kelland LR. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum coordination complex, cis[amminedichloro(2- methylpyridine)]platinum(II) (AMD473). Anticancer Drug Des 1998;13:1-18.
15. Chen Y, Zhang S, Sorani M, Giacomini KM. Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J Pharmacol Exp Ther 2007;322: 695-700.
16. Cheng JD, Valianou M, Canutescu AA, et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther 2005;4:351-360
17. Tomilets VA, Dontsov VI, Zakharova IA, Klevtsov AV. Histamine releasing and histamine binding action of platinum and palladium compounds. Arch Immunol Ther Exp (Warsz) 1980;28:953-957
18. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006;319:879-886
19. Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007;74:477-487
20. Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009;27:2046-2051
21. d'Amato TA, Landreneau RJ, Ricketts W, et al. Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 2007;133:352-363
22. Chen Y, Li S, Brown C, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 2009;19:497-504.
23. Zolk O, Solbach TF, K̈nig J, Fromm MF. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos 2009;37:1312-1318